RESUMO
The number of percutaneous radiofrequency ablation procedures performed for renal tumors is progressively increasing worldwide. Periodic imaging follow-up has the double role to guarantee the treatment efficacy over time and to early detect any possible complication. Tumor size reductions, as well as the appearance of the characteristic 'halo sign', are normal findings that represent good ablative outcomes. However the most reliable factor of ablation efficacy remains the total absence of contrast enhancing zones within the ablated area. The aim of this article is to illustrate the typical aspect of an effective radiofrequency ablation treatment, which are the imaging findings that may suggest the presence of residual tumoral tissue and which are the main early and late procedural complications.
Assuntos
Diagnóstico por Imagem , Neoplasias Renais/diagnóstico por imagem , Idoso , Idoso de 80 Anos ou mais , Diagnóstico por Imagem/métodos , Feminino , Seguimentos , Humanos , Processamento de Imagem Assistida por Computador , Neoplasias Renais/patologia , Neoplasias Renais/terapia , Imageamento por Ressonância Magnética , Masculino , Ablação por Radiofrequência/efeitos adversos , Ablação por Radiofrequência/métodos , Tomografia Computadorizada por Raios X , Resultado do TratamentoRESUMO
Glioblastoma (GBM) remains a deadly tumor. Treatment with chemo-radiotherapy and corticosteroids is known to impair the functionality of lymphocytes, potentially compromising the development of autologous CAR T cell therapies. We here generated pre-clinical investigations of autologous anti-GD2 CAR T cells tested against 2D and 3D models of GBM primary cells. We detected a robust antitumor effect, highlighting the feasibility of developing an autologous anti-GD2 CAR T cell-based therapy for GBM patients.